Cargando…

Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients

BACKGROUND: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatability of TMATV and TTB as function of uptake interval, posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolinger, Guilherme D., Vállez García, David, Kramer, Gerbrand M., Frings, Virginie, Smit, Egbert F., de Langen, Adrianus J., Dierckx, Rudi A. J. O., Hoekstra, Otto S., Boellaard, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367490/ https://www.ncbi.nlm.nih.gov/pubmed/30734113 http://dx.doi.org/10.1186/s13550-019-0481-1

Ejemplares similares

Effects of Tracer Uptake Time in Non–Small Cell Lung Cancer (18)F-FDG PET Radiomics
por: Kolinger, Guilherme D., et al.
Publicado: (2022)

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation
por: van Velden, Floris H. P., et al.
Publicado: (2016)

Validation of [(18)F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor
por: Iqbal, R., et al.
Publicado: (2018)

FDG uptake, a surrogate of tumour hypoxia?
por: Dierckx, Rudi Andre, et al.
Publicado: (2008)

Impact of [(18)F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology
por: Cheebsumon, Patsuree, et al.
Publicado: (2011)

Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer
por: Hoyng, Lieke L, et al.
Publicado: (2015)

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
por: Borm, Frank J., et al.
Publicado: (2023)

Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy
por: Niemeijer, Anna-Larissa Nadia, et al.
Publicado: (2020)

Total (18)F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
por: Fiebrich, Helle-Brit, et al.
Publicado: (2011)

Amyloid burden quantification depends on PET and MR image processing methodology
por: Kolinger, Guilherme D., et al.
Publicado: (2021)

(18)F-FDG-PET uptake in non-infected total hip prostheses
por: Gelderman, Stefan J, et al.
Publicado: (2018)

Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis
por: Cheebsumon, Patsuree, et al.
Publicado: (2011)

Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
por: van Velden, Floris H. P., et al.
Publicado: (2011)

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
por: Boellaard, Ronald, et al.
Publicado: (2014)

Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies
por: Peretti, Débora E., et al.
Publicado: (2019)

Total Cystectomy in the Treatment of Bladder Tumours
por: Mack, Wm. S.
Publicado: (1946)

Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging
por: Boellaard, Ronald, et al.
Publicado: (2010)

Correction: Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies
por: Peretti, Débora E., et al.
Publicado: (2019)

A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [(18)F]MK-6240
por: Kolinger, Guilherme D., et al.
Publicado: (2021)

Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[(18)F]fluorothymidine Positron Emission Tomography
por: Frings, Virginie, et al.
Publicado: (2013)

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
por: Boellaard, Ronald, et al.
Publicado: (2009)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

Parametric Imaging of [(11)C]Flumazenil Binding in the Rat Brain
por: Lopes Alves, Isadora, et al.
Publicado: (2017)

Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)
por: Beauregard, Jean-Mathieu, et al.
Publicado: (2021)

Partial volume correction strategies for quantitative FDG PET in oncology
por: Hoetjes, Nikie J., et al.
Publicado: (2010)

Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma
por: Kawashima, Atsunari, et al.
Publicado: (2020)

Prognostic value of baseline total metabolic tumour volume of (18)F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma
por: Gong, Huanyu, et al.
Publicado: (2021)

Use of population input functions for reduced scan duration whole-body Patlak (18)F-FDG PET imaging
por: van Sluis, Joyce, et al.
Publicado: (2021)

Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis
por: Cysouw, Matthijs C. F., et al.
Publicado: (2017)

Repeatability of (18)F‐FDG PET radiomic features: A phantom study to explore sensitivity to image reconstruction settings, noise, and delineation method
por: Pfaehler, Elisabeth, et al.
Publicado: (2018)

Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics
por: Cysouw, M. C. F., et al.
Publicado: (2019)

Measurement of metabolic tumor volume: static versus dynamic FDG scans
por: Cheebsumon, Patsuree, et al.
Publicado: (2011)

Steroid hormones affect binding of the sigma ligand (11)C-SA4503 in tumour cells and tumour-bearing rats
por: Rybczynska, Anna A., et al.
Publicado: (2009)

Mitigation of noise-induced bias of PET radiomic features
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain
por: Lopes Alves, Isadora, et al.
Publicado: (2017)

Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology
por: Cheebsumon, Patsuree, et al.
Publicado: (2012)

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
por: de Jong, Evelyn E. C., et al.
Publicado: (2016)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
por: Santaniello, Antonio, et al.
Publicado: (2019)

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
por: Kejík, Zdeněk, et al.
Publicado: (2021)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mt4buib42p2lbkqhnlu69drmp1